Alignment Healthcare reports Q1 2026 earnings after the bell today, April 30. The stock sits at $21.72 — roughly flat for the year. But the business has never grown this fast.
Here are the numbers heading into tonight’s report, and where the actual risk lives.
## FY2025: The Growth Was Real
$3.95 billion in revenue for FY2025, up 46.1% year-over-year. Q4 alone delivered $1.013 billion (+44.4%). Health plan membership ended the year at 236,300, up 25%. Five-year compound annual growth rates: 36% for revenue, 29% for membership.
For Q1, consensus calls for $1.22 billion in revenue and $0.01 EPS. Alignment guided $1,205M-$1,225M revenue, $26M-$36M adjusted EBITDA, and 281,000-285,000 members.
The 2026 full-year guide: $5.14B-$5.19B revenue (30-31% growth), $133M-$163M adjusted EBITDA, and 292,000-298,000 members by year-end.
## Why Medicare Advantage Matters Here
ALHC operates exclusively in Medicare Advantage — the privatized Medicare segment covering roughly 33 million Americans in 2026, about 54% of all Medicare beneficiaries. That penetration rate has climbed every year since 2004. Roughly 10,000 Americans age into Medicare eligibility every single day.
Alignment’s specific angle: they target the chronic/special needs population within MA. These are the most expensive members — multiple chronic conditions, high utilization. The bet is that intensive care coordination and narrow-network provider partnerships can reduce total medical costs below what CMS pays in risk-adjusted premiums. When it works, you keep the spread. The adjusted MLR was 87.2% in Q3 2025, down from 89.6% a year prior. That 240 basis point improvement is the difference between burning cash and printing it.
## Three Numbers to Watch Tonight
**Medical Loss Ratio.** Q3’s 87.2% was the best reading in company history. If Q1 holds below 87%, the care management model is proving it works at scale. Above 89%? Margins compress fast and the story gets wobbly.
**Membership vs. 285,000.** The Q1 guide midpoint is 283,000. Anything above 285,000 is a beat and sets up the full-year 295,000 target nicely. Membership drives everything — each new member is recurring premium revenue.
**SG&A as % of revenue.** Dropped from 13.1% to 11.1% in Q3. Continuing operating leverage is what turns a fast-growing insurer into a profitable one.
## The Bull Case
ALHC is the fastest-growing publicly traded Medicare Advantage company by revenue growth rate. Period.
At ~$4.5 billion market cap with $5.1-5.2B in 2026 guided revenue, you’re paying 0.87x sales for 30%+ growth. UnitedHealth trades at 1.4x sales with 8% growth. Humana trades at 0.9x with declining enrollment. On a growth-adjusted basis, ALHC is cheaper than both.
FXEmpire flagged a bull pennant on the daily chart with breakout above $22.55 and a measured target around $26.50 — near the post-IPO high of $28.02 from April 2021.
Fourteen analysts cover the stock with an average target of $21.93 — basically the current price. A strong Q1 print triggers upgrades and target raises, not just price action.
## The Bear Case (Read This Twice)
**Small-scale risk.** 236,000 members. UnitedHealth has 8 million in MA. At this size, one bad quarter of medical costs — a bad flu season, one expensive claimant, a network disruption — can swing MLR by 200-300 basis points and erase profitability. This is the core risk of small-cap health insurance.
**No GAAP profits yet.** FY2025 still showed a GAAP operating loss. The $133-163M adjusted EBITDA guidance for 2026 sounds decent until you divide by $5.1B in revenue — that’s a 2.6-3.2% margin. UnitedHealth’s Optum Health runs at 8-9%. The gap between here and mature margins is measured in years, not quarters.
**Geographic concentration.** ALHC operates in a limited number of counties across a handful of states. Expansion requires state regulatory approvals, network building, and brand recognition that takes years to establish.
**CMS rate risk.** MA benchmark rates get adjusted annually. A less favorable rate notice from the current administration cuts into per-member revenue without reducing care obligations. MA payment policy lives in a political blender.
## Valuation
$21.72 per share, ~207 million shares outstanding, ~$4.5 billion market cap. Price-to-sales: 0.87x against 2026 guidance. EV/EBITDA at the midpoint ($148M): roughly 29x. Expensive for an insurer, justifiable if you think margins expand to 5%+ by 2027.
The 52-week range: $15.50 (August 2025) to $24.78 (February 2026). Current price is in the upper half, reflecting growing confidence but not yet pricing in a blowout Q1.
## Verdict
**Compelling below $20** where growth-adjusted valuation becomes hard to ignore. **Reasonable at $21-22** if you trust tonight’s print. **Harder to justify above $25** without a clear line of sight to 5%+ EBITDA margins.
If you buy, size for volatility. One bad MLR quarter can drop this 15-20%. This is not a set-it-and-forget-it position.
**My move:** Wait for the print. If MLR holds below 87%, membership clears 285K, and guidance edges up, the pennant breakout triggers and $26+ is in play. If MLR deteriorates or membership disappoints, the stock gives back the February-March gains and you get a cleaner entry later.
Either way, ALHC is one of the few legitimate pure-play Medicare Advantage growth stories left in the mid-cap space. Worth your attention tonight.
—
This article is for informational purposes only and does not constitute financial advice. Always do your own research and consider consulting with a financial advisor before making investment decisions.